Dekabank Deutsche Girozentrale Reduces $4M in Arcutis Biotherapeutics, Inc. ($ARQT)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dekabank Deutsche Girozentrale reduced its position in Arcutis Biotherapeutics, Inc. ($ARQT), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Arcutis Biotherapeutics, Inc. after selling 140,000 shares during the quarter.
Arcutis Biotherapeutics, Inc. Stock Up 10.3%
Shares of Arcutis Biotherapeutics, Inc. ($ARQT) traded around $26.22 on Saturday, up 10.3% for the day.
Arcutis Biotherapeutics, Inc. Earnings
Analysts Set New Price Targets
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Get Arcutis Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARQT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.